OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Josh Armenia on Impact of Mutated Gene Analysis in Prostate Cancer

February 22nd 2017

Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the impact of a gene mutation analysis study in prostate cancer.

Dr. Wierda on Ibrutinib Plus Venetoclax in CLL

February 22nd 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses a clinical trial exploring the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL).

Dr. Goy on Efficacy With Ibrutinib in MCL

February 22nd 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy reported with ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL).

Dr. Kalinsky on Optical Imaging for HER2+ Breast Cancer

February 21st 2017

Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses the potential advantages of optical imaging for patients with HER2-positive breast cancer.

Dr. Albertsmeier on Radiation Therapy for Soft Tissue Sarcoma

February 21st 2017

Marcus Albertsmeier, MD, surgeon at Ludwig Maximilian University of Munich, discusses the effect of radiation therapy on local recurrence and overall survival for patients with soft tissue sarcoma.

Dr. Seiwert on Ongoing Trials in Head and Neck Cancer

February 20th 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses ongoing clinical trials in the field of head and neck cancer.

Dr. Mascarenhas Discusses Pacritinib in Myelofibrosis

February 20th 2017

John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses pacritinib in patients with myelofibrosis.

Dr. Smith on Immunotherapy Potential in Multiple Myeloma

February 20th 2017

Eric Smith, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy in the treatment landscape of multiple myeloma.

Dr. Kelly on BT062 Combination With Lenalidomide for R/R Myeloma

February 20th 2017

Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses indatuximab ravtansine (BT062) in combination with lenalidomide (Revlimid) in patients with relapsed or refractory multiple myeloma.

Dr. Spratt on Combination of Immunotherapy and Radiation in Prostate Cancer

February 18th 2017

Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses the combination of immunotherapy and radiation in patients with prostate cancer.

Dr. Wilky on Pembrolizumab Plus Axitinib in Sarcoma

February 18th 2017

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses a phase II trial exploring concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in advanced alveolar soft part sarcoma and other soft tissue sarcomas.

Dr. Woyach on Phase II Trial of MOR208 Trial in CLL

February 18th 2017

Jennifer A. Woyach, MD, an associate professor of Medicine in the Division of Internal Medicine at The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of the CD19-directed antibody MOR208 in combination with lenalidomide (Revlimid) or ibrutinib (Imbruvica) in patients with CLL.

Dr. Herrera on Next Steps of Drug Combinations for Hodgkin Lymphoma

February 17th 2017

Alex Herrera, MD, assistant professor, Department of Hematology and Hematologic Cell Transplantation, City of Hope, discusses next steps for a phase I/II study of brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) in patients with relapsed or refractory Hodgkin lymphoma.

Dr. Gordon on Immunotherapy Treatment for Osteosarcoma

February 17th 2017

Nancy B. Gordon, MD, assistant professor, department of pediatrics, The University of Texas MD Anderson Center, discusses immunotherapy treatments for osteosarcoma.

Dr. Tallman on the State of the Science in AML Treatment

February 17th 2017

Martin S. Tallman, MD, hematologic oncologist, chief of Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses the state of the science with regards to treatment of patients with acute myeloid leukemia (AML).

Dr. Neelapu on ZUMA-1 Trial Design of KTE-C19

February 17th 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the design of the ZUMA-1 trial of the chimeric antigen receptor (CAR) T-cell therapy KTE-C19 for patients with aggressive lymphomas.

Dr. Ansell on PD-1 Inhibitors in Hodgkin Lymphoma

February 17th 2017

Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses the use of PD-1 inhibitors for patients with Hodgkin lymphoma.

Dr. Dreicer on Future Treatment Approaches in Prostate Cancer

February 17th 2017

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the progress he would like to see accomplished in the field of metastatic castration-resistant prostate cancer.

Dr. Vokes on Different Settings in Head and Neck Cancer

February 16th 2017

Everett Vokes, MD, John E. Ultmann professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses different settings of patients with head and neck cancer.

Dr. Thompson on Advancements in Treatments of Multiple Myeloma

February 16th 2017

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses advancements of treatments for patients with multiple myeloma.